Kuros BiosciencesCSBTF 71 Median PS Value is $64.55 as of Jun. 27, 2026, which is 8283% above its 10-year median of 0.77. GuruFocus rates CSBTF with a GF Score™ of 71/100 and a GF Value™ of $54.72 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 338 Medical Devices & Instruments companies, Kuros Biosciences ranks better than 78.99% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Kuros Biosciences's Median PS Value or its related term are showing as below:
CSBTF'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.19 Med: 0.77 Max: 20.45
Current: 0.35
During the past 13 years, the highest Price to Median PS Value of Kuros Biosciences was 20.45. The lowest was 0.19. And the median was 0.77.
CSBTF's Price-to-Median-PS-Value is ranked better than 78.99% of 338
companies
in the Medical Devices & Instruments industry
Industry Median: 0.71
vs CSBTF: 0.35
Kuros Biosciences (OTCPK:CSBTF) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Kuros Biosciences's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
22.72
/
64.55
=
0.35
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences Median PS Value Related Terms
Kuros Biosciences Median PS Value Historical Data
* Premium members only.
The historical data trend for Kuros Biosciences's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSBTF vs ABT, SYK, MDT: Median PS Value Comparison
For the Medical Devices subindustry, Kuros Biosciences's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences Price-to-Median-PS-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 14.7949.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kuros Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $4.363.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences (CSBTF) has a Median PS Value of $64.55 as of Jun. 27, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Kuros Biosciences and its competitors. This is 8283% above median its historical median of 0.77. Over the past decade, Kuros Biosciences' Median PS Value has ranged from 0.19 to 20.45. According to the industry distribution chart, Kuros Biosciences ranks #71 out of 338 companies in the Medical Devices & Instruments industry, placing it in the top 21%.
Is Kuros Biosciences' Median PS Value too high?
Kuros Biosciences' current Median PS Value of $64.55 is 8283% above median its 10-year median of 0.77. Over the past 10 years, this metric has ranged from a low of 0.19 to a high of 20.45. The Medical Devices & Instruments industry median Median PS Value is 0.71. Kuros Biosciences' value of $64.55 is 8991.5% above this industry median. Based on the distribution chart, Kuros Biosciences ranks #71 out of 338 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Kuros Biosciences has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' Median PS Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #71 out of 338 companies for Median PS Value. This places Kuros Biosciences in the top 21% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.71. Kuros Biosciences' value of $64.55 is 8991.5% above this benchmark. Historically, Kuros Biosciences' own Median PS Value has ranged from 0.19 to 20.45 over the past decade. While the company's 10-year median is 0.77 vs. the industry median of 0.71, Kuros Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Devices & Instruments company?
The median Median PS Value among Medical Devices & Instruments companies is 0.71, based on 338 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kuros Biosciences's current Median PS Value of $64.55 is 8991.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Median PS Value is 0.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current Median PS Value is $64.55, which is 8283% above median its own 10-year median of 0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $54.72, compared to a current price of $22.72 — trading 58.5% below its estimated fair value. The current Median PS Value is $64.55, which is 8283% above median its 10-year median of 0.77 and 8991.5% above the Medical Devices & Instruments industry median of 0.71. Kuros Biosciences' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current Median PS Value is $64.55 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $22.72 is trading 58.5% below its estimated GF Value™ of $54.72.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
Median PS Value: $64.55 (8283% above median its 10-year median of 0.77)
GF Value™: $54.72 vs. price of $22.72 (58.5% below fair value)
Industry Position: 8991.5% above the Medical Devices & Instruments median (#71 of 338)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
71GF Score
Get the complete analysis for CSBTF
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
